DDInter1158 DDInter706
An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease. Although demonstrably effective in treating and maintaining remission for ulcerative colitis, mesalazine has historically faced a number of issues regarding its lack of stability as a pharmaceutical agent. Throughout the late seventies and the eighties, important research initiatives developed stable mesalazine formulations like the eudragit-S coating of Asacol brand mesalazine and the Pentasa brand's encapsulation of mesalazine within microgranules. In the present day, contemporary research regarding novel methods to stabilize mesalazine continues and interest in the agent's capacity to decrease inflammatory activity and subsequently potentially reduce the risk of colorectal cancer in conditions like ulcerative colitis is maintained.[A174019,A174022]
Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulations.[L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. Bydureon BCise, an auto-injector extended-release formulation, remains available.
Mesalazine {u} (Compound) resembles {v} (Compound) Dopamine
Dopamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Mesalazine {u} (Compound) resembles {v} (Compound) Olsalazine
Olsalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Mesalazine {u} (Compound) resembles {v} (Compound) Dopamine
Dopamine {u} (Compound) resembles {v} (Compound) Dobutamine
Dobutamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Mesalazine {u} (Compound) resembles {v} (Compound) Diflunisal
Diflunisal {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Prednisone
Prednisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Mesalazine {u} (Compound) upregulates {v} (Gene) COL11A1
COL11A1 {u} (Gene) is upregulated by {v} (Compound) Digoxin
Digoxin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Exenatide
Mesalazine {u} (Compound) resembles {v} (Compound) Olsalazine
Olsalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Meclofenamic acid
Meclofenamic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Mesalazine {u} (Compound) resembles {v} (Compound) Dopamine
Dopamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alimemazine
Alimemazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Mesalazine {u} (Compound) downregulates {v} (Gene) TERF2IP
TERF2IP {u} (Gene) is upregulated by {v} (Compound) Digoxin
Digoxin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Exenatide
Mesalazine {u} (Compound) upregulates {v} (Gene) COL11A1
COL11A1 {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Mesalazine {u} (Compound) downregulates {v} (Gene) TERF2IP
TERF2IP {u} (Gene) is downregulated by {v} (Compound) Clarithromycin
Clarithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exenatide
Mesalazine (Compound) resembles Dopamine (Compound) and Dopamine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Mesalazine (Compound) resembles Olsalazine (Compound) and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Mesalazine (Compound) resembles Dopamine (Compound) and Dopamine (Compound) resembles Dobutamine (Compound) and Dobutamine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Mesalazine (Compound) resembles Diflunisal (Compound) and Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Mesalazine (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Digoxin (Compound) and Digoxin may cause a minor interaction that can limit clinical effects when taken with Exenatide
Mesalazine (Compound) resembles Olsalazine (Compound) and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid and Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Mesalazine (Compound) resembles Dopamine (Compound) and Dopamine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Mesalazine (Compound) downregulates TERF2IP (Gene) and TERF2IP (Gene) is upregulated by Digoxin (Compound) and Digoxin may cause a minor interaction that can limit clinical effects when taken with Exenatide
Mesalazine (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Dabrafenib (Compound) and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Mesalazine (Compound) downregulates TERF2IP (Gene) and TERF2IP (Gene) is downregulated by Clarithromycin (Compound) and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide